Description
Drug Info: ApoThera Drug Disease Clinical Support App
SC Administration
– Administer the full amount in the prefilled syringe
– Allow to reach room temperature prior to use
– Do not use if particulate matter or discoloration is visible; solution should be clear and colorless to pale yellow
– Rotate injection sites; avoid injecting into moles, scars, or tender, bruised, red, or hard skin.
– Prefilled syringe is available for use by patients (self-administration).
Storage
– Store intact syringes at 2°C to 8°C (36°F to 46°F).
– Do not freeze.
– Protect vials and syringes from light (store in the original package until time of use)
– Keep syringes dry
Monitoring
– Latent TB screening prior to therapy initiation (all patients)
– Neutrophils, platelets, ALT/AST (prior to therapy, 4 to 8 weeks after start of therapy, and every 3 months thereafter [rheumatoid arthritis])
– Neutrophils, platelets, ALT/AST (prior to therapy, at second infusion, and every 2 to 4 weeks [systemic juvenile idiopathic arthritis] or 4 to 8 weeks [polyarticular juvenile idiopathic arthritis] thereafter)
– Additional liver function tests (bilirubin) as clinically indicated
– Lipid panel (prior to, at 4 to 8 weeks following initiation, and approximately every 6 months during therapy)
– Monitor all patients for signs and symptoms of infection (prior to, during, and after therapy)
– Signs and symptoms of CNS demyelinating disorders
